Proteomic Identification of Pterostilbene-mediated Anticancer Activities in HepG2 Cells
Overview
Authors
Affiliations
In the present study, we attempt to shed light on the underlying molecular mechanism of the anticancer activity of pterostilbene (PTS) in HepG2 cells through the proteomic approach. PTS was found to induce apoptosis by altering the expression of apoptotic genes and the G2/M phase of cell cycle arrest. Further, the 2-DE map showed the expression of 72 differentially regulated proteins in PTS-treated HepG2 cells, of which 8 spots with >2 fold up- or down-regulated level were identified by MALDI-TOF analysis, which has a regulatory role in apoptosis. These findings for the first time offer valuable insights into the mechanism of apoptotis by PTS in HepG2 cells.
Kabil M, Abdel Gaber S, Hamzawy M, El-Sherbiny I, Nasr M Drug Deliv Transl Res. 2023; 14(5):1338-1351.
PMID: 37930630 DOI: 10.1007/s13346-023-01467-9.
Ganesh G, Ramkumar K Inflammopharmacology. 2023; 31(4):2133-2145.
PMID: 36662400 DOI: 10.1007/s10787-023-01134-y.
A Review of the Pharmacological Potential of Dunn on Cancer.
Zhang F, Ganesan K, Liu Q, Chen J Cells. 2022; 11(18).
PMID: 36139460 PMC: 9497142. DOI: 10.3390/cells11182885.
Decreased DHRS2 expression is associated with HDACi resistance and poor prognosis in ovarian cancer.
Han Y, Wang Z, Sun S, Zhang Z, Liu J, Jin X Epigenetics. 2019; 15(1-2):122-133.
PMID: 31423895 PMC: 6961673. DOI: 10.1080/15592294.2019.1656155.
Kong Y, Li B, Chang S, Gao L, Xu Z, He W Cancer Manag Res. 2019; 11:4797-4808.
PMID: 31213901 PMC: 6549748. DOI: 10.2147/CMAR.S194202.